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The study was performed at Oslo University Hospital, Rikshospitalet, Department of 
Cardiology, POB 4950 Nydalen, 0424 Oslo, Norway.
Running head: Effect of rosuvastatin assessed with IMR
Page 2 of 50
Catheterization and Cardiovascular Interventions
































































Introduction: Many women undergoing coronary angiography for chest pain have no or only 
minimal coronary artery disease (CAD). However, despite the lack of obstructive CAD, they 
still have an increased risk of major adverse cardiovascular events. Pleiotropic effects of 
statins may influence microvascular function, but if statins improve microvascular function in 
unselected chest pain patients is not well studied. This study assessed microvascular function 
by using the thermodilution-derived test “the index of microvascular resistance” (IMR) with 
the aim of determining the (i) IMR level in women with chest pain and non-obstructive CAD 
and if (ii) IMR is modified by high-dose statin treatment in these patients. Additional 
objectives were to identify the influence of statins on the health status as assessed with 
generic health questionnaires and on biomarkers of endothelial activation.
Materials and Methods: The study was a randomized, double-blind, single-centre trial 
comparing 6 months of rosuvastatin treatment with placebo. In total, 66 women without 
obstructive CAD were included. Mean age was 52.7 years and 55.5 years in the placebo and 
rosuvastatin group, respectively. Microvascular function was assessed using the IMR, health 
status was assessed using the SF-36 and EQ-5D questionnaires, and biochemical values were 
assessed at baseline and 6 months later.
Results and Conclusions: In the placebo group IMR was 14.6 (SD 5.7) at baseline and 14.4 
(SD 6.5) at follow-up. In the rosuvastatin group IMR was 16.5 (SD 7.5) at baseline and 14.2 
(SD 5.8) at follow-up. IMR did not differ significantly between the two study groups at 
follow-up controlled for preintervention values. C-reactive protein (CRP) was comparable 
between the groups at baseline, while at follow-up CRP was significantly lower in the 
rosuvastatin group compared to placebo [0.6 (±0.5) mg/L vs 2.6 (±3.0) mg/L; p=0.002]. 
Whereas rosuvastatin treatment for 6 months attenuated CRP levels, it did not improve 
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microvascular function as assessed by IMR. (Clinical Trials.gov NCT 01582165. EUDRACT 
(2011-002630-39.3tcAZ)
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Many women undergoing coronary angiography for chest pain have no or only minimal 
coronary artery disease (CAD) 1, 2. However, despite the lack of obstructive CAD, they still 
have an increased risk of major adverse cardiovascular events such as cardiovascular 
mortality, hospitalization for myocardial infarction, heart failure and stroke 2. Furthermore, 
persistent chest pain predicts cardiovascular adverse events 3 and is associated with impaired 
health status 4, 5. The ischaemic symptoms in non-obstructive CAD have diverse aetiologies 6. 
In addition to their cholesterol-lowering effect, statins influence microvascular function and 
endothelial activation (which constitute part of their pleiotropic effects) 7-13, at least partly 
involving increased bioavailability of nitric oxide, decreased levels of endothelin-1 and 
reduced oxidative stress 14. However, the statin effect on microvascular function in general in 
patients with chest pain and no obstructive coronary artery disease, is not well studied. The 
extent to which statins also exert endothelium-independent effects that may improve 
ischaemic symptoms in non-obstructive CAD remains unclear. Because the coronary 
microcirculation cannot be directly visualized, it needs to be assessed using indirect methods. 
One such method, available during a routine diagnostic coronary angiography, is the 
thermodilution-derived functional test, the index of microvascular resistance (IMR) 15, which 
primarily explores endothelium-independent coronary microvascular dysfunction (CMD) via 
the intravenous infusion of adenosine. 
The objectives of the present study were to determine the (i) IMR level in women with chest 
pain and non-obstructive CAD and if (ii) IMR is modified by high-dose statin treatment in 
these patients. Additional objectives were to identify how statins influence the health status as 
assessed with generic health questionnaires and biomarkers of endothelial activation. The 
study therefore aimed to study a broad spectrum of patients with chest pain without 
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significant CAD and was not limited to those with microvascular dysfunction testing the 
hypothesis that statins generally improve microvascular function, and that any improvement 
in microvascular function would improve the end-point included in the study.
MATERIALS AND METHODS
Study design
This study was a randomized, double-blind, single-centre trial comparing 6 months of 
rosuvastatin treatment with placebo. Eligible women who had been referred to receive 
coronary angiography from 2012 to 2016 were recruited for inclusion in the study. The study 
protocol was approved by the South East Department of the Norwegian Regional Committee 
for Medical and Health Research Ethics (Approval code 2011/1600) and the local review 
board of the hospital. The study was conducted in compliance with Good Clinical Practice 
and with the tenets of the Declaration of Helsinki and was registered at ClinicalTrials.gov 
(NCT 01582165) and EUDRACT (2011-002630-39.3tcAZ). 
Study design and participants
Oslo University Hospital, Rikshospitalet is a tertiary referral centre in Oslo, Norway for 
interventional cardiology. Female patients aged 30–70 years with suspected ischaemic chest 
pain and unknown coronary anatomy who were referred for coronary angiography as part of a 
diagnostic workup were eligible for inclusion in this study. In total, 81 women were screened. 
Coronary angiography revealed that 13 had obstructive CAD [defined as a fractional flow 
reserve (FFR) of ≤0.80 or at least 1 occluded major coronary artery], 1 had diffuse 
atheromatosis and other reasons for statin therapy, and 1 was unable to comply with the study 
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protocol due to panic disorder (Figure 1). Hence, 66 women with angina pectoris and normal 
or near-normal coronary angiograms with FFR exceeding the ischaemic threshold of 0.80 
were included in the study (Figure 1). Positive or equivocal findings in bicycle ergometry 
were a prerequisite for inclusion. Exclusion criteria were coronary artery stenosis ≥33% in 
any epicardial vessel, pregnancy or nursing, childbearing potential and not using 
contraception, short life expectancy, uncontrolled endocrine disease, uncontrolled arterial 
hypertension, structural heart disease, significant mental disorder including dementia or 
inability to comply with the protocol. 
After diagnostic left-heart catheterization including a coronary physiology assessment, the 
patients were randomly assigned to 6 months of treatment with rosuvastatin or placebo in a 
double-blinded fashion. Written informed consent was obtained from all patients prior to 
performing heart catheterization. 
Randomization and study drugs
The randomization scheme (in a 1:1 ratio for treatment:placebo) was generated by the Centre 
for Biostatistics and Epidemiology at the hospital using a computerized procedure. Numbered 
boxes with the placebo or the treatment drug (according to the randomization scheme) were 
consecutively dispatched to the included patients. The helpers who prepared the boxes were 
not otherwise involved in the study. Identical placebo and treatment-drug tablets were 
supplied free-of-charge by Astra Zeneca UK. The daily starting dose was 20 mg of 
rosuvastatin or the matching placebo. The same dose was given throughout the study.
Echocardiography
Transthoracic images were obtained from parasternal and apical positions recording standard 
parasternal imaging planes using high-end echocardiography scanners (Vivid 7™ or E9™, 
GE Vingmed, Horten, Norway) according to current recommendations 16. Conventional 
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greyscale cineloops as well as tissue Doppler loops and blood flow velocities as measured 
using Doppler flowmetry were recorded. Data for at least three consecutive representative 
heart beats were obtained and stored on a server. 
Heart catheterization and coronary physiological assessments
Left-heart catheterization was performed mostly using a transradial approach with a 6-French 
arterial sheath and 6-French diagnostic and guiding catheters, and only in exceptional 
circumstances via the femoral artery. At the start of the procedure, 5,000 U of heparin, 2.5 mg 
of verapamil and 200 µg of glyceryl trinitrate were administered intra-arterially. Coronary 
physiological measurements were made with a pressure- and thermistor-equipped guide wire 
(PressureWire Certus, St. Jude Medical, St. Paul, MN, USA), with 200 µg of glyceryl 
trinitrate administered via an intracoronary injection before making the measurements. 
Hyperaemia was obtained by the intravenous infusion of 140 µg/kg/min adenosine. The 
procedure has been reported previously in detail 17. In short, the aortic pressure (Pa) and distal 
coronary artery pressure (Pd) were measured in the presence and absence of hyperaemia. Both 
at baseline and during hyperaemia, 3–4 mL of room-temperature saline was injected into the 
investigated coronary artery, and the resting transit time (Tmnr) and hyperaemic transit time 
(Tmnh) were recorded. The coronary physiological indices were calculated as follows:
FFR=Pd/Pa (≤0.80 indicates myocardial ischaemia due to epicardial CAD). 
IMR=Pd×Tmnh [no definite threshold has been established, but >20.8 mmHg∙s was used to 
detect CMD based on a previous study in our hospital 17]. 
CFR=Tmnr/Tmnh (coronary flow reserve, where <2.5 or <2.0 is considered pathological).
FFR was averaged over three heart beats for which its value was the lowest.
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The continuous equalization of pressures was confirmed at the end of the procedure by 
repositioning the pressure wire in the ostium of the vessel. Care was taken to ensure that the 
coronary physiological measurements were made in approximately the same position in the 
vessel during the second heart catheterization procedure.
Health status
Health status was assessed using version 1.2 of the generic 36-item Short Form Health Survey 
(SF-36) and the 5-dimension EuroQol (EQ-5D) questionnaires at baseline and 6 months later. 
SF-36 assesses the following eight dimensions of health during the previous 4 weeks: 
Physical functioning, physical role limitations, bodily pain, general perceived health, vitality, 
social functioning, emotional role limitations and mental health 18. The SF-36 score ranges 
from 0 to 100, with higher scores indicating better health. The dimension scores were 
aggregated to provide two summary scales—the physical component summary (PCS) and 
mental component summary (MCS)—reported on a standardized scale with a mean of 50 and 
a standard deviation (SD) of 10, based on a US general population.
EQ-5D measures the current health status using five items (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression) with three response levels: no problems 
(level 1), some problems (level 2) and extreme problems (level 3) 19. This instrument also 
contains the EQVAS, a 20-cm visual analogue scale that is scored from 0 (worst imaginable 
health) to 100 (best imaginable health). The scores obtained using this descriptive system 
were further converted into a utility score using population-derived weights 20, where 0 
represents being dead and 1 represents perfect health. 
Blood sampling and measures of biomarkers
Peripheral venous blood was drawn into pyrogen-free tubes with EDTA as the anticoagulant. 
The tubes were immediately immersed in melting ice and centrifuged within 30 min at 
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2000g for 20 min to obtain platelet-poor plasma. All samples were stored at –80°C until 
being analysed. Routine blood samples were analysed by use of commercial methods.
Endothelial activation was assessed using the soluble vascular cell-adhesion molecule 1 
(sVCAM-1), von Willebrand factor (vWF) and asymmetric dimethylarginine (ADMA). C-
reactive protein (CRP) and sVCAM-1 were analysed using enzyme immunoassays with 
validated antibody pairs (R&D Systems, Stillwater, MN, USA), vWF was analysed using 
validated antibody pairs (DakoCytomation, Oslo, Norway) with a parallel diluted plasma pool 
as the standard, and ADMA were measured by high-performance liquid chromatography and 
precolumn derivatization with o-phthaldialdehyde (Sigma Chemicals, St. Louis, MO, USA), 
as described in detail elsewhere with minor modifications 21. The intra- and interassay 
coefficients of variation for all measurements were <10%. 
Statistical analysis
The normality of the variables was assessed by examining histograms. Data are presented as 
mean±SD or n (%) values, as appropriate. The independent-samples t-test or Fisher’s exact 
test was used as appropriate to assess differences betwee  groups.
The effects of the intervention on coronary physiology indices, health status and biomarkers 
of endothelial activation in the treatment group compared to the placebo group were assessed 
using multiple linear regression analyses. The 6-month values were used as the dependent 
variable according to randomization groups and controlled for preintervention values, and 
only subjects with paired observations were included in the analysis. 
Statistical analyses were performed with IBM SPSS Statistics (version 24, IBM, Armonk, 
NY, USA). The threshold for statistical significance was set at p<0.05, and all tests were two-
sided.
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Among the 81 patients invited to participate, 66 patients were randomized into the 
rosuvastatin and placebo groups. The characteristics of the excluded patients did not differ 
significantly from those of the included patients (e.g., age, blood work, health status and 
echocardiographically assessed ejection fraction; data not shown), with the exception of the 
mean diastolic blood pressure being higher in the non-randomized group (81 mmHg vs 76 
mmHg, p=0.01). The characteristics of the final study population consisting of 33 patients in 
each group were well balanced with respect to age, medical history, medications and blood-
work assessments (Table 1). Overall, 10 patients were lost to follow-up (5 in each group): 2 
did not take the study drug, 1 declined a second left-heart catheterization and 7 simply did not 
attend the scheduled follow-up. Apart from the total serum cholesterol level being lower in 
subjects lost to follow-up, there were no statistically significant differences in baseline 
characteristics between patients lost to follow-up and patients who completed follow-up (data 
not shown). The medications taken (angiotensin-converting enzyme inhibitors, angiotensin II 
receptor blockers, beta-blockers, calcium-channel blockers and aspirin) were comparable 
between the two study groups both at the baseline and follow-up investigations (Tables 1 and 
2). There were no adverse events necessitating withdrawal of the study drugs. Tablet counts at 
the 6-month follow-up revealed a prescription adherence rate of >80% among all patients who 
completed the 6-month follow-up.
Coronary physiological assessments
IMR was 14.6 (SD 5.7) mmHg∙s in the placebo group and 16.5 (SD 7.5) mmHg∙s in the 
rosuvastatin group (p=0.24) at baseline (Table 3). Similarly, there were no differences in other 
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haemodynamic or coronary physiology measurements and indices at the baseline assessment, 
except for the mean resting heart rate being higher in the placebo group (p=0.05) (Table 3).  
Microvascular dysfunction defined as IMR >20.8 mmHg∙s was observed in 11 (17%) patients 
at baseline (3 and 8 in the placebo and rosuvastatin groups, respectively), with no difference 
at follow-up (4 and 6 patients, respectively). Similarly, CFR was <2.5 in six patients in each 
group, with no differences between the two groups at follow-up (four and three patients in the 
rosuvastatin and placebo groups, respectively). At the 6-month follow-up, IMR was 14.4 (SD 
6.5) mmHg∙s in the placebo group and 14.2 (SD 5.8) mmHg∙s in the rosuvastatin group. IMR, 
FFR, CFR and relevant haemodynamic measures did not differ significantly between the two 
study groups at follow-up cont olled for preintervention values (Table 3). 
Health status
The PCS and MCS scores for SF-36 and the EQVAS and EQ-5D scores at baseline and 
follow-up for both groups are listed in Table 4. Linear regression analysis of the effect of 6 
months of rosuvastatin treatment compared to placebo and controlled for the preintervention 
assessments revealed no statistically significant differences in health-status scores (Table 4).
Biochemical effects
As expected, the cholesterol levels at the 6-month follow-up were significantly lower in the 
rosuvastatin group than in the placebo group (Table 3). Importantly, at 6-month follow-up, the 
CRP levels were also significantly lower in the rosuvastatin group than with placebo (Table 
3). In contrast, natriuretic peptides, troponins and markers of endothelial activation (i.e., vWF, 
sVCAM-1 and ADMA) showed no differences between the placebo and rosuvastatin groups 
at the follow-up controlled for preintervention values (Table 3). 
DISCUSSION
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The key finding of this randomized, double-blinded study of 66 unselected women with chest 
pain but with no obstructive CAD was that 6 months of high-dose statin treatment did not 
significantly influence IMR values (Figure 2), health status or markers of endothelial 
activation. In contrast, the lipid profile was significantly improved, and the CRP levels 
significantly reduced in the rosuvastatin group. IMR values were comparable to values in a 
healthy reference population previously reported from our hospital 17. In total 17% of the 
study population had IMR values indicating CMD.
To the best of our knowledge, this is the first double-blind, randomized study to explore the 
effect of statins on IMR values in women with chest pain and without obstructive CAD. 
Whereas rosuvastatin showed significant effects on lipid and CRP levels, it showed no effect 
on IMR, the occurrence of CMD defined as IMR >20.8 mmHg∙s or markers of endothelial 
activation (Figure 3). The effects of statins on CMD have previously been studied in various 
settings but comparing the results of the present study with those of previous studies is 
difficult due to the small number of studies and the differences in end points and study 
designs. A study of the acute effect of atorvastatin showed a significant increase in the 
transthoracic Doppler-derived CFR in the atorvastatin group compared to no change in the 
placebo group 8. The effect of statins on the Doppler-derived CFR was studied in 20 patients 
with angiographically slow coronary flow (20 mg of atorvastatin daily for 8 months) 13 and in 
56 hypertensive patients (10 mg of rosuvastatin daily for 12 months) 22, with both studies 
showing significant increases in CFR. However, these were not placebo-controlled studies, 
which may explain the divergent results compared to the current study.
A positive effect of statin treatment on endothelium-dependent vasodilatation as assessed by 
flow-mediated dilatation in the peripheral arteries has been demonstrated in studies of women 
with syndrome X 23-25. However, it might not be valid to extrapolate these findings to the 
current study since adenosine primarily assesses endothelium-independent vasodilatation, and 
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the effects on the peripheral vessels may differ from those on the cardiac vasculature. 
Previous studies of the effects of statins administered prior to percutaneous coronary 
interventions indicate that statin pretreatment is beneficial to the IMR 26, 27; however, the 
relevance of this finding to the current study is disputable, since epicardial CAD was an 
exclusion criterion.
Experimental studies have suggested that statins can exert endothelium-independent 
vasodilatation effects 28, 29, but clinical studies involving humans have been lacking. Our 
findings do not unambiguously support an endothelium-independent effect of rosuvastatin, 
since there was no statistically significant decrease in IMR after 6 months. Moreover, 
although rosuvastatin down-regulated the lipid and CRP levels, it did not affect markers of 
endothelial activation. However, reduction of CRP is prognostically important as shown 
among others in the Jupiter trial 9, 11. The short follow-up period in this study may explain 
lacking improvements in other outcome measures.  Previous reviews have found conflicting 
effects of statins on ADMA, sVCAM-1 and vWF 30-33. A possible explanation that needs to be 
investigated further is that such effects would require pre-existing hypercholesterolaemia, 
which was not present in the current study. Moreover, different statins might exert different 
effects. It is also possible that patients with residual inflammation could specifically benefit 
from such a therapy.
Both the SF-36 and EQ-5D scores in the present study were comparable to those found in 
previous studies of patients with stable angina or CAD 34-37. The extent to which the 
sensitivity of generic health-status instruments is comparable to that of disease-specific 
questionnaires such as the Seattle Angina Questionnaire (SAQ) and Canadian Cardiovascular 
Society Angina Classification (CCS) has been questioned 35. This correspondence may differ 
between patient populations and types of intervention. Furthermore, non-significant changes 
in SF-36 and EQ-5D scores are consistent with the lack of significant improvements in 
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microvascular function as assessed with IMR. In contrast, a previous study found that 
combination therapy with atorvastatin and ramipril improved the health status of women with 
microvascular angina, as assessed with the SAQ 25. We did not report the CCS class due to 
difficulties of classifying patients with atypical angina. 
Study limitations
The current pilot study was designed to evaluate the effects of rosuvastatin on IMR, health 
status and markers of endothelial activation. The randomization was skewed in terms of the 
IMR distribution between the two randomization groups: the mean IMR was 1.9 mmHg·s 
higher in the treatment group than in the placebo group at baseline, and the decrease of 2.3 
mmHg·s in the former compared to 0.2 mmHg·s in the latter did not reach statistical 
significance. The decrease may be attributed to a “regression to the mean” effect. In addition, 
the relatively small sample size of the study is a major limitation, which implies a risk of type 
II errors. Hence, the study power was insufficient for detecting a possible effect of 
rosuvastatin on IMR. In addition, the number of subjects lost to follow up, further weakens 
the statistical power. Based on the inclusion criteria, the study was not powered to see if 
women with CMD could represent a subgroup that will benefit from statin therapy. On the 
other hand, a major strength of the study is the repeated invasive assessment with paired 
analyses within subjects. 
CONCLUSIONS
Rosuvastatin treatment for 6 months did not improve the health status, endothelial activation 
or microvascular function as assessed with the IMR method. However, caution is needed 
when interpreting these results due to skewness of the IMR at randomization and the 
smallness of the sample, leading to the possibility of type II errors. The study was not 
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restricted to women with microvascular dysfunction (i.e., IMR >20.8 mmHg), and 
forthcoming studies should examine if these women could have an effect of statin 
intervention.  
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Figure legends
Figure 1. 
Patient flow chart. CAD, coronary artery disease; FU, follow-up.
Figure 2.
Effect of rosuvastatin on IMR at baseline and 6-month follow-up compared to placebo, mean 
values±SD. p=0.55 for IMR at 6-month follow-up in the rosuvastatin group compared to the 
placebo group controlled for preintervention values (multiple linear regression).
Figure 3.
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In addition to improvement of lipid profile, statins exhibit anti-inflammatory effects known to 
inhibit progression and development of epicardial coronary artery disease. Despite significant 
decrease of total cholesterol, LDL-cholesterol and CRP; coronary microvascular function as 
assessed with IMR was not significantly improved.
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Table 1. Baseline characteristics of the included patients. Data are mean±SD or n (%) values. 
 Placebo (n=33) Rosuvastatin (n=33) 
Age, years 52.7±9.2 55.5±9.2 
Body mass index, kg/m
2
       26.5±4.8       25.8±4.1 
Hypertension 7 (21) 8 (24) 
Diabetes mellitus 1 (3) 1 (3) 
Current or former smoker 24 (73) 20 (61) 
Family history of CAD 27 (82) 26 (79) 
Dyslipidaemia (n=33/32)* 4 (12) 4 (12) 
Typical angina 16 (49) 18 (55) 
Atypical angina 17 (51) 15 (45) 




ACEi/ARB  4 (12)  4 (12) 
Beta blocker  12 (36) 8 (24) 
Calcium-channel blocker 4 (12) 2 (6) 
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Aspirin 25 (76) 19 (58) 
   
Biochemistry    
Total cholesterol, mmol/L 5.7±1.3 5.8±1.0 
LDL, mmol/L 3.7±1.2 3.7±0.8 
HDL, mmol/L 1.6±0.5 1.7±0.5 
Triglycerides, mmol/L 1.6±0.8 1.4±0.6 
Haemoglobin, g/dL       13.8±0.9     14.0±0.8 
Creatinine, µmol/L 65±11 64±7 
Uric acid, µmol/L (n=22/21)* 274±62 266±57 
HbA1c, % 5.6±0.4 5.6±0.5 
NT-pro-BNP,  pmol/L (n=30/27)* 7.8±5.6 13.1±12.8 
Troponin T, ng/L 7.6±2.5 7.5±2.4 
CRP, mg/L 2.1±2.5 1.2±1.1 
vWF, arbitrary units (n=32/32)* 370±244 379±195 
ADMA, µmol/mL (n=31/33)* 0.55±0.09 0.54±0.09  
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*n=denotes numbers in placebo/rosuvastatin groups, respectively. 
CAD, coronary artery disease; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; HbA1c, glycated haemoglobin; NT-pro-BNP, N-terminal-pro-brain-natriuretic peptide; CRP, C-
reactive protein; ADMA, asymmetric dimethylarginine; sVCAM-1, soluble vascular-cell adhesion molecule 1; E, peak velocity of early 
transmitral Doppler flow; e’, early diastolic tissue Doppler mitral annular velocity.   
sVCAM-1, μg/mL (n=32/32)* 1.2±1.2 1.3±0.5 
Echocardiography   
Interventricular septum diameter, cm (n=33/32)* 0.8±0.2 0.8±0.1 
Left ventricular end-diastolic diameter, cm (n=33/32)* 4.8±0.4 4.7±0.5 
Left ventricular posterior wall diameter, cm (n=32/32)*  0.7±0.1 0.7±0.1 
Left atrium area, cm
2
 (n=33/32)* 18.9±4.2 19.3±3.0 
Right atrium area, cm
2
 (n=32/29)* 16.5±3.1 16.2±2.8 
E/e’, ratio (n=32/30)* 8.5±2.2 8.1±2.8 
Cardiac index, L/min/m
2
 (n=30/31)* 2.8±0.4 2.6±0.5 
Ejection fraction, % (n=32/33)* 60.5±6.6 61.3±6.0 
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Table 2. Cardiac medication and biochemistry at follow-up. Data are mean±SD or n (%) values. 
 Placebo (n=29) Rosuvastatin (n=28) p ** 
Relevant cardiac medication   
ACEi/ARB 3 (10) 6 (21) 0.30 
Beta blocker 7 (24) 8 (29) 0.78 
Calcium-channel blocker 2 (7) 2 (7) 1.0 
Aspirin 17 (59) 11 (39) 0.19 
    
Biochemistry     
Total cholesterol, mmol/L 5.6±1.3 3.9±0.8 <0.001 
LDL, mmol/L 3.6±1.2 1.8±0.7 <0.001 
HDL, mmol/L 1.5±0.5 1.9±0.5 0.03 
Triglycerides, mmol/L (n=23, 25) * 1.6±0.7 0.9±0.4 <0.001 
Haemoglobin, g/dL 13.9±0.7 13.9±1.0        0.77 
Creatinine, µmol/L 67±10 66±10  0.49 
Uric acid, µmol/L (n=19, 13) * 305±107 267±54 0.24 
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*n=denotes numbers in placebo/rosuvastatin groups. 
** Independent-samples t-test or Fisher’s exact test as appropriate. 
*** p values for comparisons between rosuvastatin and placebo groups after 6-month follow-up controlled for preintervention values (multiple 
linear regression analysis). 
 
HbA1c, % (n=27, 27) 5.5±0.4 5.6±0.6 0.53 
NT-pro-BNP, pmol/L (n=18/18) * 7.4±5.9 11.8±8.0 0.07 
Troponin T, ng/L (n=29/27) * 6.7±2.2 6.9±2.3 0.75 
CRP, mg/L (n=28/27) * 2.6±3.0 0.6±0.5   0.002 
vWF, arbitrary units (n=27/24)* 389±245 373±232 0.62*** 
ADMA, µmol/L (n=26/26)* 0.54±0.08 0.53±0.10 0.73*** 
sVCAM, μg/mL (n=27/24)* 1.3±0.6 1.2±0.5 0.22*** 
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Table 3. Haemodynamic and coronary physiology measures at baseline and follow-up. Data are mean±SD values. 
 
 Placebo  Rosuvastatin   
 Baseline (n=33)     Follow-up (n=28) Baseline (n=33)                Follow-up (n=28) p* 
Aortic systolic pressure, mmHg 117±17 111±12 116±17 113±17 0.78 
Aortic diastolic pressure, mmHg        66±10     67±7 64±6 63±7      0.14 
Heart rate at baseline, beats/min 75±9**           73±9 70±11** 68±11 0.25 
Heart rate at maximum hyperaemia, 
beats/min 
   91±14 90±15 87±12 84±12 0.28 
Pa at maximum hyperaemia, mmHg  78±12 77±11 78±11 75±9 0.36 
Pd at maximum hyperaemia, mmHg  71±13 71±12 71±10 70±8 0.40 
Tmnr, s 0.81±0.29 0.93±0.46 0.95±0.41 0.96±0.41 0.30 
Tmnh, s 0.21±0.09 0.20±0.08 0.23±0.10 0.21±0.10 0.84 
FFR  0.91±0.05  0.92±0.04 0.92±0.04 0.93±0.04 0.68 
CFR        4.3±2.0         5.3±3.2 4.6±2.2 5.2±2.7 0.89 
IMR, mmHg·s      14.6±5.7       14.4±6.5 16.5±7.5 14.2±5.8 0.55 
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* p values for comparisons between rosuvastatin and placebo groups after 6-month follow-up controlled for preintervention values (multiple 
linear regression analysis).   
** p=0.05 for difference in heart rate at baseline between the two study groups. 
Pa, aortic pressure; Pd, distal coronary artery pressure; Tmnr, resting transit time; Tmnh, hyperaemic transit time ; FFR, fractional flow reserve; 
CFR, coronary flow reserve; IMR, index of microvascular resistance. 
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Table 4. Health-related quality-of-life scores of included patients at baseline and follow-up. Data are mean±SD values.  
 Placebo Rosuvastatin   
 Baseline (n=31) Follow-up (n=28)  Baseline (n=32) Follow-up (n=29) p* 
SF-36      
Physical functioning 73.9±20.7 78.8±17.8 74.7±17.6 86.0±14.5 0.15 
Physical role limitations       38.7±37.6      55.4±45.8     48.4±40.1      69.8±38.0 0.43 
Bodily pain 52.7±16.0 55.5±23.7 54.8±25.2 60.1±25.0 0.67 
General perceived health 60.4±18.3 66.3±21.8 62.2±22.0 72.1±23.2 0.26 
Vitality 36.6±22.4 44.6±23.6 42.4±23.6 54.8±22.1 0.42 
Social functioning 71.4±28.0 76.3±25.5 75.8±23.8 78.5±23.6 0.97 
Emotional role limitations 74.2±41.0 82.1±33.3 67.7±41.0 79.8±36.7 (n=28) 0.65 
Mental health 76.5±11.6 79.3±14.1 73.5±15.4 78.4±15.3 0.57 
Physical component summary** 39.0±9.3 42.4±10.6 (n=27) 41.5±10.5 47.1±10.4 (n=28) 0.67 
Mental component summary** 48.9±8.8 50.9±8.7 (n=27) 47.9±11.3 50.3±10.0 (n=28) 0.52 
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SF-36, 36-item Short Form Health Survey; EQ-5D, 5-dimension EuroQol; EQVAS, EQ-5D visual analogue scale. 
* p values for comparisons between rosuvastatin and placebo groups after 6-month follow-up controlled for preintervention values (multiple 
linear regression analysis). 
**Standardized for comparison with a US general population (mean of 50 and an SD of 10). 
 
      
EQ-5D      
EQVAS  61±20 (n=30) 70±18 (n=29) 67±18 (n=29) 75±21 0.88 
EQ-5D index 0.66±0.22 (n=30) 0.81±0.13 (n=29) 0.72±0.23 0.78±0.22 0.21 
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Patient flow chart. CAD, coronary artery disease; FU, follow-up. 
338x190mm (300 x 300 DPI) 
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Effect of rosuvastatin on IMR at baseline and 6-month follow-up compared to placebo, mean values±SD. 
p=0.55 for IMR at 6-month follow-up in the rosuvastatin group compared to the placebo group controlled for 
preintervention values (multiple linear regression). 
338x190mm (300 x 300 DPI) 
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In addition to improvement of lipid profile, statins exhibit anti-inflammatory effects known to inhibit 
progression and development of epicardial coronary artery disease. Despite significant decrease of total 
cholesterol, LDL-cholesterol and CRP; coronary microvascular function as assessed with IMR was not 
significantly improved. 
338x190mm (300 x 300 DPI) 
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The study was performed at Oslo University Hospital, Rikshospitalet, Department of 
Cardiology, POB 4950 Nydalen, 0424 Oslo, Norway.
Running head: Effect of rosuvastatin assessed with IMR
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Introduction: Many women undergoing coronary angiography for chest pain have no or only 
minimal coronary artery disease (CAD). However, despite the lack of obstructive CAD, they 
still have an increased risk of major adverse cardiovascular events. Pleiotropic effects of 
statins may influence microvascular function, but if statins improve microvascular function in 
unselected chest pain patients is not well studied. This study assessed microvascular function 
by using the thermodilution-derived test “the index of microvascular resistance” (IMR) with 
the aim of determining the (i) IMR level in women with chest pain and non-obstructive CAD 
and if (ii) IMR is modified by high-dose statin treatment in these patients. Additional 
objectives were to identify the influence of statins on the health status as assessed with 
generic health questionnaires and on biomarkers of endothelial activation.
Materials and Methods: The study was a randomized, double-blind, single-centre trial 
comparing 6 months of rosuvastatin treatment with placebo. In total, 66 women without 
obstructive CAD were included. Mean age was 52.7 years and 55.5 years in the placebo and 
rosuvastatin group, respectively. Microvascular function was assessed using the IMR, health 
status was assessed using the SF-36 and EQ-5D questionnaires, and biochemical values were 
assessed at baseline and 6 months later.
Results and Conclusions: In the placebo group IMR was 14.6 (SD 5.7) at baseline and 14.4 
(SD 6.5) at follow-up. In the rosuvastatin group IMR was 16.5 (SD 7.5) at baseline and 14.2 
(SD 5.8) at follow-up. IMR did not differ significantly between the two study groups at 
follow-up controlled for preintervention values. C-reactive protein (CRP) was comparable 
between the groups at baseline, while at follow-up CRP was significantly lower in the 
rosuvastatin group compared to placebo [0.6 (±0.5) mg/L vs 2.6 (±3.0) mg/L; p=0.002]. 
Whereas rosuvastatin treatment for 6 months attenuated CRP levels, it did not improve 
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microvascular function as assessed by IMR. (Clinical Trials.gov NCT 01582165. EUDRACT 
(2011-002630-39.3tcAZ)
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Many women undergoing coronary angiography for chest pain have no or only minimal 
coronary artery disease (CAD) 1, 2. However, despite the lack of obstructive CAD, they still 
have an increased risk of major adverse cardiovascular events such as cardiovascular 
mortality, hospitalization for myocardial infarction, heart failure and stroke 2. Furthermore, 
persistent chest pain predicts cardiovascular adverse events 3 and is associated with impaired 
health status 4, 5. The ischaemic symptoms in non-obstructive CAD have diverse aetiologies 6. 
In addition to their cholesterol-lowering effect, statins influence microvascular function and 
endothelial activation (which constitute part of their pleiotropic effects) 7-13, at least partly 
involving increased bioavailability of nitric oxide, decreased levels of endothelin-1 and 
reduced oxidative stress 14. However, the statin effect on microvascular function in general in 
patients with chest pain and no obstructive coronary artery disease, is not well studied. The 
extent to which statins also exert endothelium-independent effects that may improve 
ischaemic symptoms in non-obstructive CAD remains unclear. Because the coronary 
microcirculation cannot be directly visualized, it needs to be assessed using indirect methods. 
One such method, available during a routine diagnostic coronary angiography, is the 
thermodilution-derived functional test, the index of microvascular resistance (IMR) 15, which 
primarily explores endothelium-independent coronary microvascular dysfunction (CMD) via 
the intravenous infusion of adenosine. 
The objectives of the present study were to determine the (i) IMR level in women with chest 
pain and non-obstructive CAD and if (ii) IMR is modified by high-dose statin treatment in 
these patients. Additional objectives were to identify how statins influence the health status as 
assessed with generic health questionnaires and biomarkers of endothelial activation. The 
study therefore aimed to study a broad spectrum of patients with chest pain without 
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significant CAD and was not limited to those with microvascular dysfunction testing the 
hypothesis that statins generally improve microvascular function, and that any improvement 
in microvascular function would improve the end-point included in the study.
MATERIALS AND METHODS
Study design
This study was a randomized, double-blind, single-centre trial comparing 6 months of 
rosuvastatin treatment with placebo. Eligible women who had been referred to receive 
coronary angiography from 2012 to 2016 were recruited for inclusion in the study. The study 
protocol was approved by the South East Department of the Norwegian Regional Committee 
for Medical and Health Research Ethics (Approval code 2011/1600) and the local review 
board of the hospital. The study was conducted in compliance with Good Clinical Practice 
and with the tenets of the Declaration of Helsinki and was registered at ClinicalTrials.gov 
(NCT 01582165) and EUDRACT (2011-002630-39.3tcAZ). 
Study design and participants
Oslo University Hospital, Rikshospitalet is a tertiary referral centre in Oslo, Norway for 
interventional cardiology. Female patients aged 30–70 years with suspected ischaemic chest 
pain and unknown coronary anatomy who were referred for coronary angiography as part of a 
diagnostic workup were eligible for inclusion in this study. In total, 81 women were screened. 
Coronary angiography revealed that 13 had obstructive CAD [defined as a fractional flow 
reserve (FFR) of ≤0.80 or at least 1 occluded major coronary artery], 1 had diffuse 
atheromatosis and other reasons for statin therapy, and 1 was unable to comply with the study 
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protocol due to panic disorder (Figure 1). Hence, 66 women with angina pectoris and normal 
or near-normal coronary angiograms with FFR exceeding the ischaemic threshold of 0.80 
were included in the study (Figure 1). Positive or equivocal findings in bicycle ergometry 
were a prerequisite for inclusion. Exclusion criteria were coronary artery stenosis ≥33% in 
any epicardial vessel, pregnancy or nursing, childbearing potential and not using 
contraception, short life expectancy, uncontrolled endocrine disease, uncontrolled arterial 
hypertension, structural heart disease, significant mental disorder including dementia or 
inability to comply with the protocol. 
After diagnostic left-heart catheterization including a coronary physiology assessment, the 
patients were randomly assigned to 6 months of treatment with rosuvastatin or placebo in a 
double-blinded fashion. Written informed consent was obtained from all patients prior to 
performing heart catheterization. 
Randomization and study drugs
The randomization scheme (in a 1:1 ratio for treatment:placebo) was generated by the Centre 
for Biostatistics and Epidemiology at the hospital using a computerized procedure. Numbered 
boxes with the placebo or the treatment drug (according to the randomization scheme) were 
consecutively dispatched to the included patients. The helpers who prepared the boxes were 
not otherwise involved in the study. Identical placebo and treatment-drug tablets were 
supplied free-of-charge by Astra Zeneca UK. The daily starting dose was 20 mg of 
rosuvastatin or the matching placebo. The same dose was given throughout the study.
Echocardiography
Transthoracic images were obtained from parasternal and apical positions recording standard 
parasternal imaging planes using high-end echocardiography scanners (Vivid 7™ or E9™, 
GE Vingmed, Horten, Norway) according to current recommendations 16. Conventional 
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greyscale cineloops as well as tissue Doppler loops and blood flow velocities as measured 
using Doppler flowmetry were recorded. Data for at least three consecutive representative 
heart beats were obtained and stored on a server. 
Heart catheterization and coronary physiological assessments
Left-heart catheterization was performed mostly using a transradial approach with a 6-French 
arterial sheath and 6-French diagnostic and guiding catheters, and only in exceptional 
circumstances via the femoral artery. At the start of the procedure, 5,000 U of heparin, 2.5 mg 
of verapamil and 200 µg of glyceryl trinitrate were administered intra-arterially. Coronary 
physiological measurements were made with a pressure- and thermistor-equipped guide wire 
(PressureWire Certus, St. Jude Medical, St. Paul, MN, USA), with 200 µg of glyceryl 
trinitrate administered via an intracoronary injection before making the measurements. 
Hyperaemia was obtained by the intravenous infusion of 140 µg/kg/min adenosine. The 
procedure has been reported previously in detail 17. In short, the aortic pressure (Pa) and distal 
coronary artery pressure (Pd) were measured in the presence and absence of hyperaemia. Both 
at baseline and during hyperaemia, 3–4 mL of room-temperature saline was injected into the 
investigated coronary artery, and the resting transit time (Tmnr) and hyperaemic transit time 
(Tmnh) were recorded. The coronary physiological indices were calculated as follows:
FFR=Pd/Pa (≤0.80 indicates myocardial ischaemia due to epicardial CAD). 
IMR=Pd×Tmnh [no definite threshold has been established, but >20.8 mmHg∙s was used to 
detect CMD based on a previous study in our hospital 17]. 
CFR=Tmnr/Tmnh (coronary flow reserve, where <2.5 or <2.0 is considered pathological).
FFR was averaged over three heart beats for which its value was the lowest.
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The continuous equalization of pressures was confirmed at the end of the procedure by 
repositioning the pressure wire in the ostium of the vessel. Care was taken to ensure that the 
coronary physiological measurements were made in approximately the same position in the 
vessel during the second heart catheterization procedure.
Health status
Health status was assessed using version 1.2 of the generic 36-item Short Form Health Survey 
(SF-36) and the 5-dimension EuroQol (EQ-5D) questionnaires at baseline and 6 months later. 
SF-36 assesses the following eight dimensions of health during the previous 4 weeks: 
Physical functioning, physical role limitations, bodily pain, general perceived health, vitality, 
social functioning, emotional role limitations and mental health 18. The SF-36 score ranges 
from 0 to 100, with higher scores indicating better health. The dimension scores were 
aggregated to provide two summary scales—the physical component summary (PCS) and 
mental component summary (MCS)—reported on a standardized scale with a mean of 50 and 
a standard deviation (SD) of 10, based on a US general population.
EQ-5D measures the current health status using five items (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression) with three response levels: no problems 
(level 1), some problems (level 2) and extreme problems (level 3) 19. This instrument also 
contains the EQVAS, a 20-cm visual analogue scale that is scored from 0 (worst imaginable 
health) to 100 (best imaginable health). The scores obtained using this descriptive system 
were further converted into a utility score using population-derived weights 20, where 0 
represents being dead and 1 represents perfect health. 
Blood sampling and measures of biomarkers
Peripheral venous blood was drawn into pyrogen-free tubes with EDTA as the anticoagulant. 
The tubes were immediately immersed in melting ice and centrifuged within 30 min at 
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2000g for 20 min to obtain platelet-poor plasma. All samples were stored at –80°C until 
being analysed. Routine blood samples were analysed by use of commercial methods.
Endothelial activation was assessed using the soluble vascular cell-adhesion molecule 1 
(sVCAM-1), von Willebrand factor (vWF) and asymmetric dimethylarginine (ADMA). C-
reactive protein (CRP) and sVCAM-1 were analysed using enzyme immunoassays with 
validated antibody pairs (R&D Systems, Stillwater, MN, USA), vWF was analysed using 
validated antibody pairs (DakoCytomation, Oslo, Norway) with a parallel diluted plasma pool 
as the standard, and ADMA were measured by high-performance liquid chromatography and 
precolumn derivatization with o-phthaldialdehyde (Sigma Chemicals, St. Louis, MO, USA), 
as described in detail elsewhere with minor modifications 21. The intra- and interassay 
coefficients of variation for all measurements were <10%. 
Statistical analysis
The normality of the variables was assessed by examining histograms. Data are presented as 
mean±SD or n (%) values, as appropriate. The independent-samples t-test or Fisher’s exact 
test was used as appropriate to assess differences betwee  groups.
The effects of the intervention on coronary physiology indices, health status and biomarkers 
of endothelial activation in the treatment group compared to the placebo group were assessed 
using multiple linear regression analyses. The 6-month values were used as the dependent 
variable according to randomization groups and controlled for preintervention values, and 
only subjects with paired observations were included in the analysis. 
Statistical analyses were performed with IBM SPSS Statistics (version 24, IBM, Armonk, 
NY, USA). The threshold for statistical significance was set at p<0.05, and all tests were two-
sided.
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Among the 81 patients invited to participate, 66 patients were randomized into the 
rosuvastatin and placebo groups. The characteristics of the excluded patients did not differ 
significantly from those of the included patients (e.g., age, blood work, health status and 
echocardiographically assessed ejection fraction; data not shown), with the exception of the 
mean diastolic blood pressure being higher in the non-randomized group (81 mmHg vs 76 
mmHg, p=0.01). The characteristics of the final study population consisting of 33 patients in 
each group were well balanced with respect to age, medical history, medications and blood-
work assessments (Table 1). Overall, 10 patients were lost to follow-up (5 in each group): 2 
did not take the study drug, 1 declined a second left-heart catheterization and 7 simply did not 
attend the scheduled follow-up. Apart from the total serum cholesterol level being lower in 
subjects lost to follow-up, there were no statistically significant differences in baseline 
characteristics between patients lost to follow-up and patients who completed follow-up (data 
not shown). The medications taken (angiotensin-converting enzyme inhibitors, angiotensin II 
receptor blockers, beta-blockers, calcium-channel blockers and aspirin) were comparable 
between the two study groups both at the baseline and follow-up investigations (Tables 1 and 
2). There were no adverse events necessitating withdrawal of the study drugs. Tablet counts at 
the 6-month follow-up revealed a prescription adherence rate of >80% among all patients who 
completed the 6-month follow-up.
Coronary physiological assessments
IMR was 14.6 (SD 5.7) mmHg∙s in the placebo group and 16.5 (SD 7.5) mmHg∙s in the 
rosuvastatin group (p=0.24) at baseline (Table 3). Similarly, there were no differences in other 
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haemodynamic or coronary physiology measurements and indices at the baseline assessment, 
except for the mean resting heart rate being higher in the placebo group (p=0.05) (Table 3).  
Microvascular dysfunction defined as IMR >20.8 mmHg∙s was observed in 11 (17%) patients 
at baseline (3 and 8 in the placebo and rosuvastatin groups, respectively), with no difference 
at follow-up (4 and 6 patients, respectively). Similarly, CFR was <2.5 in six patients in each 
group, with no differences between the two groups at follow-up (four and three patients in the 
rosuvastatin and placebo groups, respectively). At the 6-month follow-up, IMR was 14.4 (SD 
6.5) mmHg∙s in the placebo group and 14.2 (SD 5.8) mmHg∙s in the rosuvastatin group. IMR, 
FFR, CFR and relevant haemodynamic measures did not differ significantly between the two 
study groups at follow-up cont olled for preintervention values (Table 3). 
Health status
The PCS and MCS scores for SF-36 and the EQVAS and EQ-5D scores at baseline and 
follow-up for both groups are listed in Table 4. Linear regression analysis of the effect of 6 
months of rosuvastatin treatment compared to placebo and controlled for the preintervention 
assessments revealed no statistically significant differences in health-status scores (Table 4).
Biochemical effects
As expected, the cholesterol levels at the 6-month follow-up were significantly lower in the 
rosuvastatin group than in the placebo group (Table 3). Importantly, at 6-month follow-up, the 
CRP levels were also significantly lower in the rosuvastatin group than with placebo (Table 
3). In contrast, natriuretic peptides, troponins and markers of endothelial activation (i.e., vWF, 
sVCAM-1 and ADMA) showed no differences between the placebo and rosuvastatin groups 
at the follow-up controlled for preintervention values (Table 3). 
DISCUSSION
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The key finding of this randomized, double-blinded study of 66 unselected women with chest 
pain but with no obstructive CAD was that 6 months of high-dose statin treatment did not 
significantly influence IMR values (Figure 2), health status or markers of endothelial 
activation. In contrast, the lipid profile was significantly improved, and the CRP levels 
significantly reduced in the rosuvastatin group. IMR values were comparable to values in a 
healthy reference population previously reported from our hospital 17. In total 17% of the 
study population had IMR values indicating CMD.
To the best of our knowledge, this is the first double-blind, randomized study to explore the 
effect of statins on IMR values in women with chest pain and without obstructive CAD. 
Whereas rosuvastatin showed significant effects on lipid and CRP levels, it showed no effect 
on IMR, the occurrence of CMD defined as IMR >20.8 mmHg∙s or markers of endothelial 
activation (Figure 3). The effects of statins on CMD have previously been studied in various 
settings but comparing the results of the present study with those of previous studies is 
difficult due to the small number of studies and the differences in end points and study 
designs. A study of the acute effect of atorvastatin showed a significant increase in the 
transthoracic Doppler-derived CFR in the atorvastatin group compared to no change in the 
placebo group 8. The effect of statins on the Doppler-derived CFR was studied in 20 patients 
with angiographically slow coronary flow (20 mg of atorvastatin daily for 8 months) 13 and in 
56 hypertensive patients (10 mg of rosuvastatin daily for 12 months) 22, with both studies 
showing significant increases in CFR. However, these were not placebo-controlled studies, 
which may explain the divergent results compared to the current study.
A positive effect of statin treatment on endothelium-dependent vasodilatation as assessed by 
flow-mediated dilatation in the peripheral arteries has been demonstrated in studies of women 
with syndrome X 23-25. However, it might not be valid to extrapolate these findings to the 
current study since adenosine primarily assesses endothelium-independent vasodilatation, and 
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the effects on the peripheral vessels may differ from those on the cardiac vasculature. 
Previous studies of the effects of statins administered prior to percutaneous coronary 
interventions indicate that statin pretreatment is beneficial to the IMR 26, 27; however, the 
relevance of this finding to the current study is disputable, since epicardial CAD was an 
exclusion criterion.
Experimental studies have suggested that statins can exert endothelium-independent 
vasodilatation effects 28, 29, but clinical studies involving humans have been lacking. Our 
findings do not unambiguously support an endothelium-independent effect of rosuvastatin, 
since there was no statistically significant decrease in IMR after 6 months. Moreover, 
although rosuvastatin down-regulated the lipid and CRP levels, it did not affect markers of 
endothelial activation. However, reduction of CRP is prognostically important as shown 
among others in the Jupiter trial 9, 11. The short follow-up period in this study may explain 
lacking improvements in other outcome measures.  Previous reviews have found conflicting 
effects of statins on ADMA, sVCAM-1 and vWF 30-33. A possible explanation that needs to be 
investigated further is that such effects would require pre-existing hypercholesterolaemia, 
which was not present in the current study. Moreover, different statins might exert different 
effects. It is also possible that patients with residual inflammation could specifically benefit 
from such a therapy.
Both the SF-36 and EQ-5D scores in the present study were comparable to those found in 
previous studies of patients with stable angina or CAD 34-37. The extent to which the 
sensitivity of generic health-status instruments is comparable to that of disease-specific 
questionnaires such as the Seattle Angina Questionnaire (SAQ) and Canadian Cardiovascular 
Society Angina Classification (CCS) has been questioned 35. This correspondence may differ 
between patient populations and types of intervention. Furthermore, non-significant changes 
in SF-36 and EQ-5D scores are consistent with the lack of significant improvements in 
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microvascular function as assessed with IMR. In contrast, a previous study found that 
combination therapy with atorvastatin and ramipril improved the health status of women with 
microvascular angina, as assessed with the SAQ 25. We did not report the CCS class due to 
difficulties of classifying patients with atypical angina. 
Study limitations
The current pilot study was designed to evaluate the effects of rosuvastatin on IMR, health 
status and markers of endothelial activation. The randomization was skewed in terms of the 
IMR distribution between the two randomization groups: the mean IMR was 1.9 mmHg·s 
higher in the treatment group than in the placebo group at baseline, and the decrease of 2.3 
mmHg·s in the former compared to 0.2 mmHg·s in the latter did not reach statistical 
significance. The decrease may be attributed to a “regression to the mean” effect. In addition, 
the relatively small sample size of the study is a major limitation, which implies a risk of type 
II errors. Hence, the study power was insufficient for detecting a possible effect of 
rosuvastatin on IMR. In addition, the number of subjects lost to follow up, further weakens 
the statistical power. Based on the inclusion criteria, the study was not powered to see if 
women with CMD could represent a subgroup that will benefit from statin therapy. On the 
other hand, a major strength of the study is the repeated invasive assessment with paired 
analyses within subjects. 
CONCLUSIONS
Rosuvastatin treatment for 6 months did not improve the health status, endothelial activation 
or microvascular function as assessed with the IMR method. However, caution is needed 
when interpreting these results due to skewness of the IMR at randomization and the 
smallness of the sample, leading to the possibility of type II errors. The study was not 
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restricted to women with microvascular dysfunction (i.e., IMR >20.8 mmHg), and 
forthcoming studies should examine if these women could have an effect of statin 
intervention.  
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Figure legends
Figure 1. 
Patient flow chart. CAD, coronary artery disease; FU, follow-up.
Figure 2.
Effect of rosuvastatin on IMR at baseline and 6-month follow-up compared to placebo, mean 
values±SD. p=0.55 for IMR at 6-month follow-up in the rosuvastatin group compared to the 
placebo group controlled for preintervention values (multiple linear regression).
Figure 3.
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In addition to improvement of lipid profile, statins exhibit anti-inflammatory effects known to 
inhibit progression and development of epicardial coronary artery disease. Despite significant 
decrease of total cholesterol, LDL-cholesterol and CRP; coronary microvascular function as 
assessed with IMR was not significantly improved.
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